{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T09:26:44Z","timestamp":1777627604584,"version":"3.51.4"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T00:00:00Z","timestamp":1664236800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T00:00:00Z","timestamp":1664236800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["312215\/2021-5"],"award-info":[{"award-number":["312215\/2021-5"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Purinergic Signalling"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1007\/s11302-022-09898-8","type":"journal-article","created":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T04:02:32Z","timestamp":1664251352000},"page":"387-399","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["The antidepressant-like effect of guanosine involves the modulation of adenosine A1 and A2A receptors"],"prefix":"10.1007","volume":"19","author":[{"given":"Anderson","family":"Camargo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis E. B.","family":"Bettio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priscila B.","family":"Rosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia M.","family":"Rosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Glorister A.","family":"Alt\u00ea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana L\u00facia S.","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,9,27]]},"reference":[{"key":"9898_CR1","doi-asserted-by":"crossref","unstructured":"World Health Organization (2017) Depression and other common mental disorders: global health estimates. World Health Organization 1\u201324","DOI":"10.7591\/9780801463921-002"},{"key":"9898_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nrdp.2016.65","volume":"2","author":"C Otte","year":"2016","unstructured":"Otte C, Gold S, Penninx B et al (2016) Major depressive disorder. Nat Rev Dis Primers 2:1\u201320. https:\/\/doi.org\/10.1038\/nrdp.2016.65","journal-title":"Nat Rev Dis Primers"},{"key":"9898_CR3","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.ejphar.2015.12.029","volume":"771","author":"MP Kaster","year":"2016","unstructured":"Kaster MP, Moretti M, Cunha MP, Rodrigues ALS (2016) Novel approaches for the management of depressive disorders. Eur J Pharmacol 771:236\u2013240. https:\/\/doi.org\/10.1016\/j.ejphar.2015.12.029","journal-title":"Eur J Pharmacol"},{"key":"9898_CR4","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1038\/mp.2015.92","volume":"20","author":"GI Papakostas","year":"2015","unstructured":"Papakostas GI, Ionescu DF (2015) Towards new mechanisms: an update on therapeutics for treatment-resistant major depressive disorder. Mol Psychiatry 20:1142\u20131150. https:\/\/doi.org\/10.1038\/mp.2015.92","journal-title":"Mol Psychiatry"},{"key":"9898_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/BRAINSCI10030160","volume":"10","author":"F Bartoli","year":"2020","unstructured":"Bartoli F, Burnstock G, Crocamo C, Carr\u00e0 G (2020) Purinergic signaling and related biomarkers in depression. Brain Sci 10:1\u201312. https:\/\/doi.org\/10.3390\/BRAINSCI10030160","journal-title":"Brain Sci"},{"key":"9898_CR6","doi-asserted-by":"publisher","first-page":"107821","DOI":"10.1016\/J.PHARMTHERA.2021.107821","volume":"224","author":"A Szopa","year":"2021","unstructured":"Szopa A, Soca\u0142a K, Serefko A et al (2021) Purinergic transmission in depressive disorders. Pharmacol Ther 224:107821. https:\/\/doi.org\/10.1016\/J.PHARMTHERA.2021.107821","journal-title":"Pharmacol Ther"},{"key":"9898_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-1-4939-9717-6_1","volume":"2041","author":"G Burnstock","year":"2020","unstructured":"Burnstock G (2020) Introduction to purinergic signaling. Methods Mol Biol 2041:1\u201315. https:\/\/doi.org\/10.1007\/978-1-4939-9717-6_1","journal-title":"Methods Mol Biol"},{"key":"9898_CR8","doi-asserted-by":"publisher","first-page":"7742","DOI":"10.1016\/S0074-7742(05)63007-3","volume":"63","author":"BB Fredholm","year":"2005","unstructured":"Fredholm BB, Chen J, Cunha RA, Svenningsson P (2005) Adenosine and brain function. Int Rev Neurobiol 63:7742.\u00a0https:\/\/doi.org\/10.1016\/S0074-7742(05)63007-3","journal-title":"Int Rev Neurobiol"},{"key":"9898_CR9","doi-asserted-by":"publisher","first-page":"105363","DOI":"10.1016\/J.PHRS.2020.105363","volume":"163","author":"JI Gomes","year":"2021","unstructured":"Gomes JI, Farinha-Ferreira M, Rei N et al (2021) Of adenosine and the blues: the adenosinergic system in the pathophysiology and treatment of major depressive disorder. Pharmacol Res 163:105363. https:\/\/doi.org\/10.1016\/J.PHRS.2020.105363","journal-title":"Pharmacol Res"},{"key":"9898_CR10","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/J.NEULET.2003.10.040","volume":"355","author":"MP Kaster","year":"2004","unstructured":"Kaster MP, Rosa AO, Rosso MM et al (2004) Adenosine administration produces an antidepressant-like effect in mice: evidence for the involvement of A1 and A2A receptors. Neurosci Lett 355:21\u201324. https:\/\/doi.org\/10.1016\/J.NEULET.2003.10.040","journal-title":"Neurosci Lett"},{"key":"9898_CR11","doi-asserted-by":"publisher","first-page":"7833","DOI":"10.1073\/pnas.1423088112","volume":"112","author":"MP Kaster","year":"2015","unstructured":"Kaster MP, Machado NJ, Silva HB et al (2015) Caffeine acts through neuronal adenosine A2A receptors to prevent mood and memory dysfunction triggered by chronic stress. Proceed National Acad Sci USA 112:7833\u20137838. https:\/\/doi.org\/10.1073\/pnas.1423088112","journal-title":"Proceed National Acad Sci USA"},{"key":"9898_CR12","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/JNC.14841","volume":"151","author":"D van Calker","year":"2019","unstructured":"van Calker D, Biber K, Domschke K, Serchov T (2019) The role of adenosine receptors in mood and anxiety disorders. J Neurochem 151:11\u201327. https:\/\/doi.org\/10.1111\/JNC.14841","journal-title":"J Neurochem"},{"key":"9898_CR13","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s11302-015-9446-7","volume":"11","author":"MP Cunha","year":"2015","unstructured":"Cunha MP, Pazini FL, Rosa JM et al (2015) Creatine, similarly to ketamine, affords antidepressant-like effects in the tail suspension test via adenosine A1and A2Areceptor activation. Purinergic Signalling 11:215\u2013227. https:\/\/doi.org\/10.1007\/s11302-015-9446-7","journal-title":"Purinergic Signalling"},{"key":"9898_CR14","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1016\/J.PNPBP.2008.01.012","volume":"32","author":"KR Lobato","year":"2008","unstructured":"Lobato KR, Binfar\u00e9 RW, Budni J et al (2008) Involvement of the adenosine A1 and A2A receptors in the antidepressant-like effect of zinc in the forced swimming test. Prog Neuropsychopharmacol Biol Psychiatry 32:994\u2013999. https:\/\/doi.org\/10.1016\/J.PNPBP.2008.01.012","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"12","key":"9898_CR15","doi-asserted-by":"publisher","first-page":"7425","DOI":"10.1038\/s41380-021-01246-3","volume":"26","author":"V Lazarevic","year":"2021","unstructured":"Lazarevic V, Yang Y, Flais I, Svenningsson P (2021) Ketamine decreases neuronally released glutamate via retrograde stimulation of presynaptic adenosine A1 receptors. Mole Psychiatry 26(12):7425\u20137435. https:\/\/doi.org\/10.1038\/s41380-021-01246-3","journal-title":"Mole Psychiatry"},{"key":"9898_CR16","doi-asserted-by":"publisher","first-page":"173422","DOI":"10.1016\/J.PBB.2022.173422","volume":"218","author":"A Camargo","year":"2022","unstructured":"Camargo A, Rodrigues ALS (2022) Guanosine as a promising target for fast-acting antidepressant responses. Pharmacol Biochem Behav 218:173422. https:\/\/doi.org\/10.1016\/J.PBB.2022.173422","journal-title":"Pharmacol Biochem Behav"},{"key":"9898_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/FPHAR.2021.652130","volume":"547","author":"RF Almeida","year":"2021","unstructured":"Almeida RF, Ferreira TP, David CVC et al (2021) Guanine-based purines as an innovative target to treat major depressive disorder. Front Pharmacol 547:1\u20136. https:\/\/doi.org\/10.3389\/FPHAR.2021.652130","journal-title":"Front Pharmacol"},{"key":"9898_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fphar.2016.00158","volume":"7","author":"V di Liberto","year":"2016","unstructured":"di Liberto V, Mud\u00f2 G, Garozzo R et al (2016) The guanine-based purinergic system: The tale of an orphan neuromodulation. Front Pharmacol 7:1\u201315.\u00a0https:\/\/doi.org\/10.3389\/fphar.2016.00158","journal-title":"Front Pharmacol"},{"key":"9898_CR19","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s11302-016-9509-4","volume":"12","author":"LEB Bettio","year":"2016","unstructured":"Bettio LEB, Gil-Mohapel J, Rodrigues ALS (2016) Guanosine and its role in neuropathologies. Purinergic Signalling 12:411\u2013426. https:\/\/doi.org\/10.1007\/s11302-016-9509-4","journal-title":"Purinergic Signalling"},{"key":"9898_CR20","doi-asserted-by":"publisher","first-page":"657","DOI":"10.14336\/AD.2016.0208","volume":"7","author":"D Lanznaster","year":"2016","unstructured":"Lanznaster D, Dal-Cim T, Piermartiri TCB, Tasca CI (2016) Guanosine: a neuromodulator with therapeutic potential in brain disorders. Aging Dis 7:657\u2013679. https:\/\/doi.org\/10.14336\/AD.2016.0208","journal-title":"Aging Dis"},{"key":"9898_CR21","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.psyneuen.2016.04.017","volume":"70","author":"T Ali-Sisto","year":"2016","unstructured":"Ali-Sisto T, Tolmunen T, Toffol E et al (2016) Purine metabolism is dysregulated in patients with major depressive disorder. Psychoneuroendocrinology 70:25\u201332. https:\/\/doi.org\/10.1016\/j.psyneuen.2016.04.017","journal-title":"Psychoneuroendocrinology"},{"issue":"1","key":"9898_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41398-020-01182-w","volume":"11","author":"RJT Mocking","year":"2021","unstructured":"Mocking RJT, Naviaux JC, Li K et al (2021) Metabolic features of recurrent major depressive disorder in remission, and the risk of future recurrence. Translational Psychiatry 11(1):1\u201313. https:\/\/doi.org\/10.1038\/s41398-020-01182-w","journal-title":"Translational Psychiatry"},{"key":"9898_CR23","doi-asserted-by":"publisher","first-page":"8429","DOI":"10.1038\/s41598-020-65300-w","volume":"10","author":"RF Almeida","year":"2020","unstructured":"Almeida RF, Pocharski CB, Rodrigues ALS et al (2020) Guanosine fast onset antidepressant-like effects in the olfactory bulbectomy mice model. Sci Rep 10:8429. https:\/\/doi.org\/10.1038\/s41598-020-65300-w","journal-title":"Sci Rep"},{"key":"9898_CR24","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.bbr.2012.06.021","volume":"234","author":"LEB Bettio","year":"2012","unstructured":"Bettio LEB, Cunha MP, Budni J et al (2012) Guanosine produces an antidepressant-like effect through the modulation of NMDA receptors, nitric oxide-cGMP and PI3K\/mTOR pathways. Behav Brain Res 234:137\u2013148. https:\/\/doi.org\/10.1016\/j.bbr.2012.06.021","journal-title":"Behav Brain Res"},{"key":"9898_CR25","doi-asserted-by":"publisher","unstructured":"Rosa PB, Bettio LEB, Neis VB et al (2021) Antidepressant-like effect of guanosine involves activation of AMPA receptor and BDNF\/TrkB signaling. Purinergic Signal 17:285\u2013301. https:\/\/doi.org\/10.1007\/s11302-021-09779-6","DOI":"10.1007\/s11302-021-09779-6"},{"key":"9898_CR26","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s11302-019-09681-2","volume":"15","author":"PB Rosa","year":"2019","unstructured":"Rosa PB, Bettio LEB, Neis VB et al (2019) The antidepressant-like effect of guanosine is dependent on GSK-3\u03b2 inhibition and activation of MAPK\/ERK and Nrf2\/heme oxygenase-1 signaling pathways. Purinergic Signalling 15:491\u2013504. https:\/\/doi.org\/10.1007\/s11302-019-09681-2","journal-title":"Purinergic Signalling"},{"key":"9898_CR27","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.jad.2020.03.186","volume":"271","author":"A Camargo","year":"2020","unstructured":"Camargo A, Dalmagro AP, Zeni ALB, Rodrigues ALS (2020) Guanosine potentiates the antidepressant-like effect of subthreshold doses of ketamine: possible role of pro-synaptogenic signaling pathway. J Affect Disord 271:100\u2013108. https:\/\/doi.org\/10.1016\/j.jad.2020.03.186","journal-title":"J Affect Disord"},{"key":"9898_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/FPSYT.2021.701408","volume":"1268","author":"RF Almeida","year":"2021","unstructured":"Almeida RF, Nonose Y, Ganzella M et al (2021) Antidepressant-like effects of chronic guanosine in the olfactory bulbectomy mouse model. Front Psych 1268:1\u201314. https:\/\/doi.org\/10.3389\/FPSYT.2021.701408","journal-title":"Front Psych"},{"key":"9898_CR29","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1111\/ejn.13172","volume":"43","author":"L Bettio","year":"2016","unstructured":"Bettio L, Neis V, Pazini F et al (2016) The antidepressant-like effect of chronic guanosine treatment is associated with increased hippocampal neuronal differentiation. Eur J Neurosci 43:1006\u20131015. https:\/\/doi.org\/10.1111\/ejn.13172","journal-title":"Eur J Neurosci"},{"key":"9898_CR30","doi-asserted-by":"publisher","first-page":"112014","DOI":"10.1016\/j.bbr.2019.112014","volume":"372","author":"NF Marques","year":"2019","unstructured":"Marques NF, Binder LB, Roversi K et al (2019) Guanosine prevents depressive-like behaviors in rats following bilateral dorsolateral striatum lesion induced by 6-hydroxydopamine. Behav Brain Res 372:112014. https:\/\/doi.org\/10.1016\/j.bbr.2019.112014","journal-title":"Behav Brain Res"},{"key":"9898_CR31","doi-asserted-by":"publisher","first-page":"3814","DOI":"10.1007\/S12035-020-01977-4","volume":"57","author":"T Piermartiri","year":"2020","unstructured":"Piermartiri T, dos Santos B, Barros-Arag\u00e3o F et al (2020) Guanosine promotes proliferation in neural stem cells from hippocampus and neurogenesis in adult mice. Mol Neurobiol 57:3814\u20133826. https:\/\/doi.org\/10.1007\/S12035-020-01977-4","journal-title":"Mol Neurobiol"},{"key":"9898_CR32","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/jnc.12324","volume":"126","author":"T Dal-Cim","year":"2013","unstructured":"Dal-Cim T, Ludka FK, Martins WC et al (2013) Guanosine controls inflammatory pathways to afford neuroprotection of hippocampal slices under oxygen and glucose deprivation conditions. J Neurochem 126:437\u2013450. https:\/\/doi.org\/10.1111\/jnc.12324","journal-title":"J Neurochem"},{"key":"9898_CR33","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/S11302-019-09679-W","volume":"15","author":"T Dal-Cim","year":"2019","unstructured":"Dal-Cim T, Poluceno GG, Lanznaster D et al (2019) Guanosine prevents oxidative damage and glutamate uptake impairment induced by oxygen\/glucose deprivation in cortical astrocyte cultures: involvement of A1 and A2A adenosine receptors and PI3K, MEK, and PKC pathways. Purinergic Signalling 15:465. https:\/\/doi.org\/10.1007\/S11302-019-09679-W","journal-title":"Purinergic Signalling"},{"key":"9898_CR34","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/S11302-021-09765-Y\/FIGURES\/3","volume":"17","author":"CM Massari","year":"2021","unstructured":"Massari CM, Constantino LC, Tasca CI (2021) Adenosine A1 and A2A receptors are involved on guanosine protective effects against oxidative burst and mitochondrial dysfunction induced by 6-OHDA in striatal slices. Purinergic Signalling 17:247\u2013254. https:\/\/doi.org\/10.1007\/S11302-021-09765-Y\/FIGURES\/3","journal-title":"Purinergic Signalling"},{"key":"9898_CR35","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/S11302-020-09716-Z","volume":"16","author":"C Massari","year":"2020","unstructured":"Massari C, Constantino L, Marques N et al (2020) Involvement of adenosine A 1 and A 2A receptors on guanosine-mediated anti-tremor effects in reserpinized mice. Purinergic Signalling 16:379\u2013387. https:\/\/doi.org\/10.1007\/S11302-020-09716-Z","journal-title":"Purinergic Signalling"},{"key":"9898_CR36","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s12035-015-9660-x","volume":"54","author":"RF Almeida","year":"2017","unstructured":"Almeida RF, Comasseto DD, Ramos DB et al (2017) Guanosine anxiolytic-like effect involves adenosinergic and glutamatergic neurotransmitter systems. Mol Neurobiol 54:423\u2013436. https:\/\/doi.org\/10.1007\/s12035-015-9660-x","journal-title":"Mol Neurobiol"},{"key":"9898_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/IJMS21239281","volume":"21","author":"M Frinchi","year":"2020","unstructured":"Frinchi M, Verdi V, Plescia F et al (2020) Guanosine-mediated anxiolytic-like effect: interplay with adenosine A1 and A2A receptors. Int J Mol Sci 21:1\u201315. https:\/\/doi.org\/10.3390\/IJMS21239281","journal-title":"Int J Mol Sci"},{"key":"9898_CR38","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/BF00428203","volume":"85","author":"L Steru","year":"1985","unstructured":"Steru L, Chermat R, Thierry B, Simon P (1985) The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology 85:367\u2013370. https:\/\/doi.org\/10.1007\/BF00428203","journal-title":"Psychopharmacology"},{"key":"9898_CR39","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/J.NEUBIOREV.2005.03.009","volume":"29","author":"JF Cryan","year":"2005","unstructured":"Cryan JF, Mombereau C, Vassout A (2005) The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice. Neurosci Biobehav Rev 29:571\u2013625. https:\/\/doi.org\/10.1016\/J.NEUBIOREV.2005.03.009","journal-title":"Neurosci Biobehav Rev"},{"key":"9898_CR40","doi-asserted-by":"publisher","first-page":"108843","DOI":"10.1016\/j.cbi.2019.108843","volume":"314","author":"AP Dalmagro","year":"2019","unstructured":"Dalmagro AP, Camargo A, Rodrigues ALS, Zeni ALB (2019) Involvement of PI3K\/Akt\/GSK-3\u03b2 signaling pathway in the antidepressant-like and neuroprotective effects of Morus nigra and its major phenolic, syringic acid. Chem Biol Interact 314:108843. https:\/\/doi.org\/10.1016\/j.cbi.2019.108843","journal-title":"Chem Biol Interact"},{"key":"9898_CR41","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/J.JPSYCHIRES.2021.09.057","volume":"144","author":"A Camargo","year":"2021","unstructured":"Camargo A, Dalmagro AP, Wolin IAV et al (2021) The resilient phenotype elicited by ketamine against inflammatory stressors-induced depressive-like behavior is associated with NLRP3-driven signaling pathway. J Psychiatr Res 144:118\u2013128. https:\/\/doi.org\/10.1016\/J.JPSYCHIRES.2021.09.057","journal-title":"J Psychiatr Res"},{"key":"9898_CR42","doi-asserted-by":"publisher","first-page":"110509","DOI":"10.1016\/J.PNPBP.2022.110509","volume":"115","author":"A Camargo","year":"2022","unstructured":"Camargo A, Torr\u00e1 ACNC, Dalmagro AP et al (2022) Prophylactic efficacy of ketamine, but not the low-trapping NMDA receptor antagonist AZD6765, against stress-induced maladaptive behavior and 4E-BP1-related synaptic protein synthesis impairment. Prog Neuropsychopharmacol Biol Psychiatry 115:110509. https:\/\/doi.org\/10.1016\/J.PNPBP.2022.110509","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"9898_CR43","doi-asserted-by":"publisher","first-page":"113459","DOI":"10.1016\/j.expneurol.2020.113459","volume":"334","author":"A Camargo","year":"2020","unstructured":"Camargo A, Dalmagro AP, de Souza MM et al (2020) Ketamine, but not guanosine, as a prophylactic agent against corticosterone-induced depressive-like behavior: possible role of long-lasting pro-synaptogenic signaling pathway. Exp Neurol 334:113459. https:\/\/doi.org\/10.1016\/j.expneurol.2020.113459","journal-title":"Exp Neurol"},{"issue":"9","key":"9898_CR44","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.1007\/S00213-021-05879-8","volume":"238","author":"A Camargo","year":"2021","unstructured":"Camargo A, Dalmagro AP, Fraga DB et al (2021) Low doses of ketamine and guanosine abrogate corticosterone-induced anxiety-related behavior, but not disturbances in the hippocampal NLRP3 inflammasome pathway. Psychopharmacology 238(9):2555\u20132568. https:\/\/doi.org\/10.1007\/S00213-021-05879-8","journal-title":"Psychopharmacology"},{"key":"9898_CR45","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/0003-2697(77)90043-4","volume":"83","author":"GLA Peterson","year":"1977","unstructured":"Peterson GLA (1977) A simplification of the protein assay method of Lowry. Anal Biochem 83:346\u2013356. https:\/\/doi.org\/10.1016\/0003-2697(77)90043-4","journal-title":"Anal Biochem"},{"key":"9898_CR46","doi-asserted-by":"publisher","first-page":"110371","DOI":"10.1016\/j.pnpbp.2021.110371","volume":"111","author":"A Camargo","year":"2021","unstructured":"Camargo A, Dalmagro AP, Wolin IAV et al (2021) A low-dose combination of ketamine and guanosine counteracts corticosterone-induced depressive-like behavior and hippocampal synaptic impairments via mTORC1 signaling. Prog Neuropsychopharmacol Biol Psychiatry 111:110371. https:\/\/doi.org\/10.1016\/j.pnpbp.2021.110371","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"9898_CR47","doi-asserted-by":"publisher","first-page":"109476","DOI":"10.1016\/j.cbi.2021.109476","volume":"342","author":"DB Fraga","year":"2021","unstructured":"Fraga DB, Camargo A, Olescowicz G et al (2021) A single administration of ascorbic acid rapidly reverses depressive-like behavior and hippocampal synaptic dysfunction induced by corticosterone in mice. Chem Biol Interact 342:109476. https:\/\/doi.org\/10.1016\/j.cbi.2021.109476","journal-title":"Chem Biol Interact"},{"key":"9898_CR48","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.jpsychires.2019.05.017","volume":"115","author":"A Camargo","year":"2019","unstructured":"Camargo A, Pazini FL, Rosa JM et al (2019) Augmentation effect of ketamine by guanosine in the novelty-suppressed feeding test is dependent on mTOR signaling pathway. J Psychiatr Res 115:103\u2013112. https:\/\/doi.org\/10.1016\/j.jpsychires.2019.05.017","journal-title":"J Psychiatr Res"},{"key":"9898_CR49","doi-asserted-by":"publisher","first-page":"104797","DOI":"10.1016\/j.neuint.2020.104797","volume":"139","author":"A Camargo","year":"2020","unstructured":"Camargo A, Dalmagro AP, Rosa MJ et al (2020) Subthreshold doses of guanosine plus ketamine elicit antidepressant-like effect in a mouse model of depression induced by corticosterone: Role of GR\/NF-\u03baB\/IDO-1 signaling. Neurochem Int 139:104797. https:\/\/doi.org\/10.1016\/j.neuint.2020.104797","journal-title":"Neurochem Int"},{"key":"9898_CR50","doi-asserted-by":"publisher","first-page":"5543","DOI":"10.1038\/S41598-021-84700-0","volume":"11","author":"IA Guedes","year":"2021","unstructured":"Guedes IA, Costa LSC, dos Santos KB et al (2021) Drug design and repurposing with DockThor-VS web server focusing on SARS-CoV-2 therapeutic targets and their non-synonym variants. Sci Rep 11:5543. https:\/\/doi.org\/10.1038\/S41598-021-84700-0","journal-title":"Sci Rep"},{"key":"9898_CR51","doi-asserted-by":"publisher","first-page":"2778","DOI":"10.1021\/CI200227U\/ASSET\/IMAGES\/LARGE\/CI-2011-00227U_0005.JPEG","volume":"51","author":"RA Laskowski","year":"2011","unstructured":"Laskowski RA, Swindells MB (2011) LigPlot+: Multiple ligand-protein interaction diagrams for drug discovery. J Chem Inf Model 51:2778\u20132786. https:\/\/doi.org\/10.1021\/CI200227U\/ASSET\/IMAGES\/LARGE\/CI-2011-00227U_0005.JPEG","journal-title":"J Chem Inf Model"},{"key":"9898_CR52","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/S0006-8993(01)02734-2","volume":"912","author":"DR Lara","year":"2001","unstructured":"Lara DR, Schmidt AP, Frizzo MES et al (2001) Effect of orally administered guanosine on seizures and death induced by glutamatergic agents. Brain Res 912:176\u2013180. https:\/\/doi.org\/10.1016\/S0006-8993(01)02734-2","journal-title":"Brain Res"},{"key":"9898_CR53","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.ejphar.2009.04.018","volume":"613","author":"AP Schmidt","year":"2009","unstructured":"Schmidt AP, B\u00f6hmer AE, Schallenberger C et al (2009) Spinal mechanisms of antinociceptive action caused by guanosine in mice. Eur J Pharmacol 613:46\u201353. https:\/\/doi.org\/10.1016\/j.ejphar.2009.04.018","journal-title":"Eur J Pharmacol"},{"key":"9898_CR54","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.pbb.2014.10.002","volume":"127","author":"LEB Bettio","year":"2014","unstructured":"Bettio LEB, Freitas AE, Neis VB et al (2014) Guanosine prevents behavioral alterations in the forced swimming test and hippocampal oxidative damage induced by acute restraint stress. Pharmacol Biochem Behav 127:7\u201314. https:\/\/doi.org\/10.1016\/j.pbb.2014.10.002","journal-title":"Pharmacol Biochem Behav"},{"key":"9898_CR55","doi-asserted-by":"publisher","first-page":"6871089","DOI":"10.1155\/2017\/6871089","volume":"2017","author":"W Liu","year":"2017","unstructured":"Liu W, Ge T, Leng Y et al (2017) The role of neural plasticity in depression: from hippocampus to prefrontal cortex. Neural Plast 2017:6871089. https:\/\/doi.org\/10.1155\/2017\/6871089","journal-title":"Neural Plast"},{"key":"9898_CR56","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/B978-0-12-801022-8.00015-5","volume":"119","author":"K Yamada","year":"2014","unstructured":"Yamada K, Kobayashi M, Kanda T (2014) Involvement of adenosine A2A receptors in depression and anxiety. Int Rev Neurobiol 119:373\u2013393. https:\/\/doi.org\/10.1016\/B978-0-12-801022-8.00015-5","journal-title":"Int Rev Neurobiol"},{"key":"9898_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/FPSYT.2014.00067","volume":"5","author":"JE Coelho","year":"2014","unstructured":"Coelho JE, Alves P, Canas PM et al (2014) Overexpression of adenosine A2A receptors in rats: effects on depression, locomotion, and anxiety. Front Psych 5:1\u20138. https:\/\/doi.org\/10.3389\/FPSYT.2014.00067","journal-title":"Front Psych"},{"key":"9898_CR58","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/J.NEURON.2015.07.010","volume":"87","author":"T Serchov","year":"2015","unstructured":"Serchov T, Clement HW, Schwarz MK et al (2015) Increased signaling via adenosine A1 receptors, sleep deprivation, imipramine, and ketamine inhibit depressive-like behavior via induction of Homer1a. Neuron 87:549\u2013562. https:\/\/doi.org\/10.1016\/J.NEURON.2015.07.010","journal-title":"Neuron"},{"key":"9898_CR59","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1124\/JPET.108.149617","volume":"330","author":"RA Hodgson","year":"2009","unstructured":"Hodgson RA, Bertorelli R, Varty GB et al (2009) Characterization of the potent and highly selective A2A receptor antagonists preladenant and SCH 412348 [7-[2-[4-2,4-difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine] in rodent models of movement disorders and depression. J Pharmacol Exp Ther 330:294\u2013303. https:\/\/doi.org\/10.1124\/JPET.108.149617","journal-title":"J Pharmacol Exp Ther"},{"key":"9898_CR60","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/J.PBB.2013.10.022","volume":"114\u2013115","author":"K Yamada","year":"2013","unstructured":"Yamada K, Kobayashi M, Mori A et al (2013) Antidepressant-like activity of the adenosine A(2A) receptor antagonist, istradefylline (KW-6002), in the forced swim test and the tail suspension test in rodents. Pharmacol Biochem Behav 114\u2013115:23\u201330. https:\/\/doi.org\/10.1016\/J.PBB.2013.10.022","journal-title":"Pharmacol Biochem Behav"},{"issue":"1","key":"9898_CR61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/tp.2012.136","volume":"3","author":"DJ Hines","year":"2013","unstructured":"Hines DJ, Schmitt LI, Hines RM et al (2013) Antidepressant effects of sleep deprivation require astrocyte-dependent adenosine mediated signaling. Translational Psychiatry 3(1):1\u20139. https:\/\/doi.org\/10.1038\/tp.2012.136","journal-title":"Translational Psychiatry"},{"key":"9898_CR62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/CELLS8121630","volume":"8","author":"D Lanznaster","year":"2019","unstructured":"Lanznaster D, Massari CM, Markov\u00e1 V et al (2019) Adenosine A1\u2013A2A receptor-receptor interaction: contribution to guanosine-mediated effects. Cells 8:1\u201316. https:\/\/doi.org\/10.3390\/CELLS8121630","journal-title":"Cells"},{"key":"9898_CR63","doi-asserted-by":"publisher","first-page":"3145","DOI":"10.1007\/S12035-018-1296-1","volume":"56","author":"F Dobrachinski","year":"2019","unstructured":"Dobrachinski F, Gerbatin RR, Sartori G et al (2019) Guanosine attenuates behavioral deficits after traumatic brain injury by modulation of adenosinergic Receptors. Mol Neurobiol 56:3145\u20133158. https:\/\/doi.org\/10.1007\/S12035-018-1296-1","journal-title":"Mol Neurobiol"},{"key":"9898_CR64","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1038\/sj.bjp.0704542","volume":"135","author":"U Traversa","year":"2002","unstructured":"Traversa U, Bombi G, di Iorio P et al (2002) Specific [(3)H]-guanosine binding sites in rat brain membranes. Br J Pharmacol 135:969\u2013976. https:\/\/doi.org\/10.1038\/sj.bjp.0704542","journal-title":"Br J Pharmacol"},{"key":"9898_CR65","doi-asserted-by":"publisher","first-page":"5417","DOI":"10.1016\/j.bmc.2003.09.043","volume":"11","author":"U Traversa","year":"2003","unstructured":"Traversa U, Bombi G, Camaioni E et al (2003) Rat brain guanosine binding site: Biological studies and pseudo-receptor construction. Bioorg Med Chem 11:5417\u20135425. https:\/\/doi.org\/10.1016\/j.bmc.2003.09.043","journal-title":"Bioorg Med Chem"},{"key":"9898_CR66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/NU12103080","volume":"12","author":"HJ Jee","year":"2020","unstructured":"Jee HJ, Lee SG, Bormate KJ, Jung YS (2020) Effect of caffeine consumption on the risk for neurological and psychiatric disorders: sex differences in Human. Nutrients 12:1\u201320. https:\/\/doi.org\/10.3390\/NU12103080","journal-title":"Nutrients"},{"key":"9898_CR67","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1002\/MNFR.201500620","volume":"60","author":"G Grosso","year":"2016","unstructured":"Grosso G, Micek A, Castellano S et al (2016) Coffee, tea, caffeine and risk of depression: a systematic review and dose-response meta-analysis of observational studies. Mol Nutr Food Res 60:223\u2013234. https:\/\/doi.org\/10.1002\/MNFR.201500620","journal-title":"Mol Nutr Food Res"}],"container-title":["Purinergic Signalling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11302-022-09898-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11302-022-09898-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11302-022-09898-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T08:26:26Z","timestamp":1686126386000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11302-022-09898-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,27]]},"references-count":67,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["9898"],"URL":"https:\/\/doi.org\/10.1007\/s11302-022-09898-8","relation":{},"ISSN":["1573-9538","1573-9546"],"issn-type":[{"value":"1573-9538","type":"print"},{"value":"1573-9546","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,27]]},"assertion":[{"value":"31 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All procedures were carried out in accordance with the National Institute of Health Guide for the Care and Use of Laboratory Animals, and the protocols were approved by the Institutional Ethics Committee.Informed consent.Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}